PMID- 18184076
OWN - NLM
STAT- MEDLINE
DCOM- 20080128
LR  - 20080110
IS  - 0889-2229 (Print)
IS  - 0889-2229 (Linking)
VI  - 23
IP  - 11
DP  - 2007 Nov
TI  - Intravenous immunoglobulin (IVIG) treatment for modulation of immune activation 
      in human immunodeficiency virus type 1 infected therapy-naive individuals.
PG  - 1348-53
LID - 10.1089/aid.2006.0210 [doi]
AB  - We evaluated the ability of intravenous immunoglobulin (IVIG) to diminish immune 
      hyperactivation, which is considered a major cause of CD4+ T cell loss during 
      chronic HIV-1 infection and whether this affected CD4+ T cell counts and plasma 
      HIV-1 RNA (pVL). Therefore, we treated six chronically HIV-1-infected, 
      antiretroviral-therapy-naive patients with IVIG (0.4 g/kg) at weeks 0 and 4, with 
      a follow-up of 12 weeks after the second dosage during which pVL, T cell numbers, 
      and T cell activation were measured. At baseline median CD4+ T cell counts were 
      300 (range 200-460) x 10(6)/liter and median pVL was 5.0 (range 3.2-5.2) log10 
      copies/ml. IgG plasma levels peaked during the first days after administration. 
      We observed a decrease in the percentage of activated (CD38+ HLA-DR+) CD4+ and 
      CD8+ T cells [3.5% (range 1-7%) and 5% (1-10%), respectively (p = 0.027)], but no 
      effect on the fraction of proliferating CD4+ or CD8+ T cells as measured by Ki67 
      expression. CD4+ T cell counts were significantly increased on day 4 (median +55 
      cells, range 0-150, p = 0.043). pVL was significantly increased on day 1 after 
      IVIG infusion (median +0.13 log10, range 0.01-0.55, p = 0.028). All these 
      parameters returned to baseline levels within 1 week after infusion. In 
      conclusion, administration of IVIG caused a temporary decrease in T cell 
      activation and an increase in CD4+ T cell counts, despite an increase in pVL. Our 
      results support the hypothesis that T cell activation, rather than direct HIV-1 
      infection, mediates the loss of CD4+ T cells and suggest that immunomodulating 
      therapy in HIV-1 infection could indeed be effective.
FAU - Vermeulen, Joost N
AU  - Vermeulen JN
AD  - IATEC, c/o Academic Medical Center of the University of Amsterdam, Amsterdam, the 
      Netherlands. j.n.vermeulen@amc.uva.nl
FAU - Prins, Jan M
AU  - Prins JM
FAU - Bunnik, Evelien
AU  - Bunnik E
FAU - Hack, C Erik
AU  - Hack CE
FAU - Jurriaans, Suzanne
AU  - Jurriaans S
FAU - Miedema, Frank
AU  - Miedema F
FAU - Lange, Joep M A
AU  - Lange JM
FAU - Schuitemaker, Hanneke
AU  - Schuitemaker H
LA  - eng
PT  - Journal Article
PL  - United States
TA  - AIDS Res Hum Retroviruses
JT  - AIDS research and human retroviruses
JID - 8709376
RN  - 0 (Immunoglobulins, Intravenous)
RN  - 0 (Ki-67 Antigen)
RN  - 0 (RNA, Viral)
SB  - IM
MH  - Adult
MH  - Aged
MH  - CD4 Lymphocyte Count
MH  - HIV Infections/*drug therapy
MH  - HIV-1/isolation & purification
MH  - Humans
MH  - Immunoglobulins, Intravenous/*therapeutic use
MH  - Ki-67 Antigen/biosynthesis
MH  - Lymphocyte Activation/*immunology
MH  - Middle Aged
MH  - RNA, Viral/blood
MH  - Viral Load
EDAT- 2008/01/11 09:00
MHDA- 2008/01/29 09:00
CRDT- 2008/01/11 09:00
PHST- 2008/01/11 09:00 [pubmed]
PHST- 2008/01/29 09:00 [medline]
PHST- 2008/01/11 09:00 [entrez]
AID - 10.1089/aid.2006.0210 [doi]
PST - ppublish
SO  - AIDS Res Hum Retroviruses. 2007 Nov;23(11):1348-53. doi: 10.1089/aid.2006.0210.